ACell, Inc. to Present at Medtech Insight and Windhover Information's ``Investment In Innovation (In3) WEST'' Conference, February 23-24, 2006, Irvine, CA.

IRVINE, Calif. -- ACell, Inc. has announced that it will be presenting at the Medtech Insight and Windhover Information's "Investment In Innovation (In3) WEST: A Preview of Early-Stage Medical Technology Companies" Conference, February 23-24, 2006 at the Hyatt Regency Irvine in Irvine, California. ACell's presentation is scheduled for Thursday, February 23rd at 11AM.

ACell Inc. is a regenerative medicine company that develops, manufactures, and markets extracellular matrix (ECM) products for medical and veterinary applications. ACell's ECM technology fundamentally changes the healing response by encouraging the body's own regenerative capabilities to repair tissues and organs, and restore them to natural health and function.

The company's technology can dramatically increase the breadth of treatment options for disease and injuries and has applicability in improving a wide variety of treatments including wound care, general surgery, urology, gastroenterology, neurology, plastic and reconstructive surgery and orthopedic and cardiovascular repair.

ACell has obtained four FDA medical device allowances for use in human wound care and general surgical indications with attractive market potential, including soft tissue trauma, lower urinary tract reconstruction, body wall repair and esophageal reconstruction. ACell's technology has additional applications that are targeted for future commercialization, including orthopaedics, cardiovascular, plastic surgery, and neurology. The total U.S. revenue opportunity for all of these applications exceeds $40 billion.

"We have demonstrated the remarkable efficacy of ACell's product in the veterinary market and in pre-clinical studies," said Jim DeFrancesco, ACell's CEO and President, "and we look forward to working with strategic partners to capture the market for current and future medical indications." ACell will begin clinical studies using UBM products in 2006.

ACell's proprietary ECM scaffold devices are derived from specific porcine urinary bladder tissues to produce a matrix, called "UBM." Since UBM is a naturally occurring, completely resorbable acellular material, it offers important advantages compared to existing tissue scaffold and regeneration technologies and products. In particular, ACell's UBM devices do not pose any of the risks associated with cell or gene therapy techniques. The products do not have the problems of permanent non-resorbable matrices, as the UBM scaffold is a naturally derived, non-crosslinked collagen-based scaffold which is gradually resorbed and replaced as new tissue is regenerated. UBM products are classified as medical devices, and therefore do not require a lengthy FDA clinical approval process. As compared to conventional scaffolds, UBM devices also exhibit several unique and highly desirable features sought by surgeons and patients:

--naturally occurring, acellular matrix improves wound healing and tissue remodeling;

--bimodal surface characteristics ideal for certain types of tissue remodeling;

--matrix rapidly degrades and is completely resorbed leaving healthy, new tissue; and

--promotes localized cell growth and angiogenesis.

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. In3 WEST is Medtech Insight's 20th investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.